Nectar Lifesciences, a company in the Pharmaceuticals industry, reported revenue of ₹0.01 crore and net profit of ₹2.72 crore for the September 2026 quarter.
Nectar Lifesciences (NSE: NECLIFE) closed at ₹9.81 on 20 Nov 2026. Its market capitalisation is ₹191 crore.
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.